White paper: Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases
Antimicrobial resistance can facilitate the emergence of new or previously recognized disease agents, and its damaging effects are increasingly being seen around the world.
This white paper highlights the challenges of emerging and re-emerging infectious diseases
such as TB, MSSA/MRSA, and Ebola and the extensive capabilities Q2 Solutions offers
in support of infectious disease clinical trials, including:
- Niche and novel assay development
- DNA & RNA extraction and next-generation sequencing
- Integrated local lab data management services
- Global laboratory network held to rigorous quality standards and biosafety protocols
Read more about how we are applying innovative technologies to provide customers insights into developing diagnostics and therapies
with enhanced efficacy against the target pathogens and their resistant variants for improved safety.
Ayaskant Pany, MD
Director, Medical Laboratory, Central Laboratories South Africa, Q2
Solutions, a Quintiles Quest Joint Venture
Dr. Pany is currently the Medical Laboratory Director, South Africa. His broad responsibilities include both administrative and technical management of the laboratory and its employees. He also oversees developmental activities for TB and microbiology at Q2
Solutions. Read Dr. Pany’s insightful perspectives on World TB Day
Sorika van Niekerk, MSc, UP, SA
Senior Director/General Manager, Central Laboratories South Africa, Q² Solutions, a Quintiles Quest Joint Venture
Sorika van Niekerk is senior director of laboratory operations for Sub-Saharan Africa with a special interest and specific strategy to increase the infectious disease footprint for the laboratory.
Stephen Mortlock, DSc.
Global Infectious Diseases and Microbiology Laison, Q2 Solutions, a Quintiles Quest Joint Venture
Dr. Stephen Mortlock is the Global Infectious Diseases and Microbiology Liaison at a Q2 Solutions laboratory in the UK.
Wayne R. Hogrefe, Ph.D., D (ABMLI)
Vice President, Vaccine unit, Q2 Solutions, a Quintiles Quest Joint Venture Company
Dr. Hogrefe is the vice president of the vaccine unit at Q2 Solutions, a Quintiles Quest Joint Venture, where he has had overall business development responsibilities for the past eight years.